

S3 navalpro
400 mg/4 ml
sodium valproate

S3 navalpro CR
sodium valproate | valproic acid

The Black and White of Grey Matter

An **affordable** [1] sodium valproate for the treatment of epilepsy

NAVALPRO is available in different dosage forms for parenteral and oral use

IMPORTANT SAFETY INFORMATION

NAVALPRO is contraindicated in pregnancy and lactation.There have been reports of foetal abnormalities in women receiving valproate during pregnancy. NAVALPRO should not be used in women of childbearing potential.

References:
1. Medikredit manufacturing pricing report, 12 April 2020.

S3 **NAVALPRO CR 200.** Reg. No.: 45/2.5/0411. Each film-coated controlled release tablet contains 133,2 mg sodium valproate and 58,0 mg valproic acid, together equivalent to 200 mg sodium valproate.
S3 **NAVALPRO CR 300.** Reg. No.: 45/2.5/0091. Each film-coated controlled release tablet contains 199,8 mg sodium valproate and 87,0 mg valproic acid, together equivalent to 300 mg sodium valproate.
S3 **NAVALPRO CR 500.** Reg. No.: 45/2.5/0092. Each film-coated controlled release tablet contains 333,0 mg sodium valproate and 145,0 mg valproic acid, together equivalent to 500 mg sodium valproate.
HCR: Brimpharm SA (Pty) Ltd. (Reg. No.: 1998/021326/07). 215 Main Road, Claremont, 7708, Cape Town, South Africa. For full prescribing information refer to the professional information approved by the medicines regulatory authority (03/2013).

S3 **NAVALPRO 400 mg/4 ml** (powder and solvent for injectable solution). Reg. No.: A40/2.5/0342. Each vial contains 400 mg freeze-dried sodium valproate. For full prescribing information refer to the professional information approved by the medicines regulatory authority (02/2012). Trademarks are owned by or licensed to the Aspen Group of companies.
Marketed by Aspen Pharmacare. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-VA-09-20-00002 09/20 MENAV2025

aspen PHARMACARE

Healthcare. We Care.

Marketed by Aspen Pharmacare
www.aspenpharma.com
Medical Hotline 0800 118 088